#BAPLA
PICSEL-ID: reverse image search and indexing that connects licensees with rights holders. Free for PICSEL and BAPLA members, fee for non-members. Link in bio for more.

#PICSELID
#VisualArtists
#BAPLA
September 9, 2026 at 2:00 PM
Bienvenue dans le Cercle BAPLA 🙏
Je m'appelle Wens, originaire de Diébougou au Burkina Faso. Ici, on parle de bien-être, d'autonomie et de positivité pour nous, les plus de 60 ans — et pour tous ceux qui veulent bien vieillir entourés.
WENS | Substack
Wens, 72 ans, une vie extraordinaire, un réseau humain rare, une plume authentique. La Lettre de Wens peut toucher beaucoup de gens.
substack.com
August 4, 2026 at 1:45 AM
À Diébougou, un arbre à palabres au centre du village était le vrai lieu de décision — pas les grandes assemblées.

Je lance le Cercle BAPLA : un arbre à palabres numérique sur WhatsApp/Telegram, où la sagesse circule dans les deux sens.

👉 wens6357.substack.
wens6357.substack
July 28, 2026 at 12:27 AM
[Feeling like the BAPLA spokesman in the sketch where the Cuba flight is hijacked by the guy who wants to go to Luton]
April 12, 2026 at 10:01 PM
Efficacy of a long lasting ivermectin formulation against malaria vectors in a semi-field trial in Bapla, Southwest of Burkina Faso bioRxivpreprint
Efficacy of a long lasting ivermectin formulation against malaria vectors in a semi-field trial in Bapla, Southwest of Burkina Faso
Background: Ivermectin, a widely used endectocide with activity against Anopheles (An) mosquitoes, has emerged as a promising complementary tool for malaria vector control. However, currently approved oral formulations provide only short-lived plasma concentrations at mosquitocidal levels, thereby limiting their operational impact. To overcome this limitation, a long-acting injectable formulation based on ivermectin and BEPO technology (mdc-STM-001) was selected through laboratory screening using mosquito colonies. This formulation demonstrated mosquitocidal efficacy meeting WHO criteria, with a hazard ratio (HR) >4 maintained for at least two months. The present study aims to further characterize the efficacy of ivermectin under robust field conditions and to expand susceptibility assessments to wild Anopheles populations representing different species and vectorial status. Ivermectin was tested in cattle at two doses under field conditions using experimental huts and tent traps. Plasma drug levels were also monitored to characterize the pharmacokinetic profile of ivermectin. Methods: Thirty-six calves were involved in the study and allocated to three groups (n = 12 per group). The mdc-STM-1.0 group received a single subcutaneous injection of the long-acting ivermectin formulation mdc-STM-001 at a dose of 1.0 mg/kg; the mdc-STM-1.5 group received the same formulation at 1.5 mg/kg and the third group served as controls. Using a three-arm design, cattle from each treatment group were simultaneously exposed to mosquitoes in experimental huts and tent traps, following a Greco-Latin Square rotation to minimize positional confounding factors. Pharmacokinetic data were collected to assess ivermectin release from the subcutaneous depot. Correlations between plasma ivermectin concentrations and mosquito mortality were explored, and survival analysis including Kaplan-Meier and cox proportional hazards models were performed to assess the effect of treatment on mosquito survival. Results: The mdc-STM-001 formulation was well tolerated and produced sustained, dose-dependent plasma ivermectin concentrations, with detectable levels maintained for more than 90 days after a single administration. Both doses induced strong mosquitocidal activity against wild Anopheles, with hazard ratios reaching 8.03 and 16.47 for the 1.0 and 1.5 mg/kg doses, respectively. An. funestus and An. rufipes were the most susceptible species (LC50: 5.1-6.9 ng/mL) exhibiting prolonged LC50 coverage (>75 days), whereas An. coustani was less susceptible (LC50: 12.4-19.2 ng/mL) resulting in a shorter duration of effective coverage (17-41 days). Conclusions: Taken together, our results revealed the potential of the mdc-STM-001 long-acting ivermectin formulation as an effective endectocide against residual malaria transmission by primary and secondary vectors and establish evidence basis to support its progression to early-phase clinical trials in humans. Keywords: Ivermectin, long-acting formulation, Anopheles, primary and secondary vectors, mortality, residual malaria, Burkina Faso
dlvr.it
August 7, 2026 at 2:43 AM
Efficacy of a long lasting ivermectin formulation against malaria vectors in a semi-field trial in Bapla, Southwest of Burkina Faso bioRxivpreprint
Efficacy of a long lasting ivermectin formulation against malaria vectors in a semi-field trial in Bapla, Southwest of Burkina Faso
Background: Ivermectin, a widely used endectocide with activity against Anopheles (An) mosquitoes, has emerged as a promising complementary tool for malaria vector control. However, currently approved oral formulations provide only short-lived plasma concentrations at mosquitocidal levels, thereby limiting their operational impact. To overcome this limitation, a long-acting injectable formulation based on ivermectin and BEPO technology (mdc-STM-001) was selected through laboratory screening using mosquito colonies. This formulation demonstrated mosquitocidal efficacy meeting WHO criteria, with a hazard ratio (HR) >4 maintained for at least two months. The present study aims to further characterize the efficacy of ivermectin under robust field conditions and to expand susceptibility assessments to wild Anopheles populations representing different species and vectorial status. Ivermectin was tested in cattle at two doses under field conditions using experimental huts and tent traps. Plasma drug levels were also monitored to characterize the pharmacokinetic profile of ivermectin. Methods: Thirty-six calves were involved in the study and allocated to three groups (n = 12 per group). The mdc-STM-1.0 group received a single subcutaneous injection of the long-acting ivermectin formulation mdc-STM-001 at a dose of 1.0 mg/kg; the mdc-STM-1.5 group received the same formulation at 1.5 mg/kg and the third group served as controls. Using a three-arm design, cattle from each treatment group were simultaneously exposed to mosquitoes in experimental huts and tent traps, following a Greco-Latin Square rotation to minimize positional confounding factors. Pharmacokinetic data were collected to assess ivermectin release from the subcutaneous depot. Correlations between plasma ivermectin concentrations and mosquito mortality were explored, and survival analysis including Kaplan-Meier and cox proportional hazards models were performed to assess the effect of treatment on mosquito survival. Results: The mdc-STM-001 formulation was well tolerated and produced sustained, dose-dependent plasma ivermectin concentrations, with detectable levels maintained for more than 90 days after a single administration. Both doses induced strong mosquitocidal activity against wild Anopheles, with hazard ratios reaching 8.03 and 16.47 for the 1.0 and 1.5 mg/kg doses, respectively. An. funestus and An. rufipes were the most susceptible species (LC50: 5.1-6.9 ng/mL) exhibiting prolonged LC50 coverage (>75 days), whereas An. coustani was less susceptible (LC50: 12.4-19.2 ng/mL) resulting in a shorter duration of effective coverage (17-41 days). Conclusions: Taken together, our results revealed the potential of the mdc-STM-001 long-acting ivermectin formulation as an effective endectocide against residual malaria transmission by primary and secondary vectors and establish evidence basis to support its progression to early-phase clinical trials in humans. Keywords: Ivermectin, long-acting formulation, Anopheles, primary and secondary vectors, mortality, residual malaria, Burkina Faso
dlvr.it
August 5, 2026 at 7:42 PM
Periodic anti-anagrams rant-ette.

Email subject line in my inbox:
"Don't Forget to Book Tickets for BAPLA FOCUS 2024"

Sender:
BAPLA

Logo header:
BAPLA

It's a while since I subscribed to British Association of Picture Libraries and Agencies, so was flummoxed right until the tiny print at bottom.
September 24, 2024 at 3:50 PM
BaPla
January 9, 2026 at 6:55 PM
Efficacy of a long lasting ivermectin formulation against malaria vectors in a semi-field trial in Bapla, Southwest of Burkina Faso https://www.biorxiv.org/content/10.64898/2026.07.31.741508v1
August 5, 2026 at 7:32 PM
A stat from the PLS Annual Conference in early July: 30% of PLS Permissions requests are for images. PICSEL-ID exists for exactly this gap, free for PICSEL and BAPLA members and available to non-members (terms apply). Link in bio.

#PICSELID
#VisualArtists
#ImageRights
July 20, 2026 at 1:38 PM
CEO Paul Seheult was honoured with the Remarkable Career & Contribution award at BAPLA Focus 2025!
The 50th anniversary event explored issues faced by our sector, inc copyright, AI & the future of creators.
@picselcollective
#BAPLA
#MakeItFair
#CollectingSociety
October 3, 2025 at 10:27 AM
PICSEL will be at BAPLA Focus again this year!
PICSEL’s CEO, Paul Seheult, will join a panel to discuss his role in the bold collective action Make It Fair campaign with his collaborators. Join us there.
#MakeItFair
#BAPLAFOCUS2025
September 22, 2025 at 10:20 AM
Thank you to everyone at BAPLA for bringing the community together to share knowledge, ideas and solutions for the future of licensing.
September 26, 2025 at 11:30 AM
Yesterday our CEO Christian Zimmermann and Head of Licensing Victoria Hooper were at BAPLA Focus 2025 in London ✨
September 26, 2025 at 11:30 AM
Efficacy of a long lasting ivermectin formulation against malaria vectors in a semi-field trial in Bapla, Southwest of Burkina Faso https://www.biorxiv.org/content/10.64898/2026.07.31.741508v1
August 5, 2026 at 7:32 PM
BAPLA FOCUS 2025: Full Programme Live + Keynote Announced!
Isabelle Doran (CEO, AOP) leads with Copyright, Control & the Creator’s Voice in the Age of AI. Celebrate BAPLA’s 50th at the Churchill War Rooms.
🎟 Tickets & programme: www.bapla.org.uk/events/bapla...

#BAPLAFocus2025 #PhotographyIndustry
August 22, 2025 at 10:26 AM